Healthcare resource utilization and cost-of-illness in systemic light chain (AL) amyloidosis in Europe: results from the real-world, retrospective EMN23 study

Systemic light chain (AL) amyloidosis is a rare clonal disease caused by immunoglobulin light chains that misfold, aggregate, and form amyloid fibrils in several critical organ systems, predominantly in the heart and kidneys ( ∼70% of patients). 1,2 The crude incidence of AL amyloidosis was 10.44 patients per million population in 2018. 3

Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2024 Category: Hematology Authors: Arnaud Jaccard, Frank Bridoux, Wilfried Roeloffzen, Monique C. Minnema, Rui Bergantim, Roman H ájek, Cristina João, M. Teresa Cibeira, Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Meletios A. Dimopoulos, Sriram Ravichandran, U Source Type: research